VIDEO: Aflibercept 8 mg shows continued anatomic improvements, safety at 96 weeks

WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye 2024, Sunir J. Garg, MD, FACS, FASRS, discusses 96-week data investigating aflibercept 8 mg for the treatment of neovascular age-related macular degeneration.
“What I am telling my patients is that we can use a drug that we have become very familiar with over the past 10 years,” he said. “We are getting similar anatomic response and over time patients were able to be dosed a lot less frequently.”

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.